Pfizer Inc
NYSE: PFE
$29.42
-$0.24 (-0.8%)
Closing Price on September 20, 2024
PFE Articles
A generic version of Viagra is coming to America, but will existing customers be willing to switch over to a generic version of the pill?
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
Disney, Intel, Pfizer, and Verizon led Tuesday's drop in the DJIA.
Published:
Last Updated:
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
Published:
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Published:
Last Updated:
When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren't enough to placate investors.
Published:
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Published:
The busiest earnings week of the season has come and gone, but there are still plenty more big names stepping into the spotlight this week.
Published:
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
Published:
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
Among the most shorted stocks traded on the New York Stock Exchange, two struggling retailers saw notable growth in their short interest in the latest reporting period.
Published:
Last Updated:
Here are 13 featured spin-offs already underway and potential spin-offs that could be seen in 2017 and into 2018 that could radically change how Wall Street and Main Street evaluate companies ahead.
Published:
Last Updated:
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated: